Immunic AG announced that two former executives of 4SC AG have joined the management team of the company and strengthen the capabilities of the company to execute its IMU-838 and IMU-366 development programs. Daniel Vitt and Hella Kohlhof have had intimate involvement in the previous development activities in both drug development programs. They also bring with them a wealth of experience and expertise in the field of treatment of autoimmune and chronic inflammatory diseases with high unmet medical need. In addition, Dr. Thomas Taapken will join Immunic's Supervisory Board. Currently, Thomas Taapken is Chief Financial Officer (CFO) at Medigene AG.

As of January 1, 2017 Dr. Daniel Vitt was appointed as new Chief Executive Officer (CEO) of Immunic AG. Prior to this position, he was Chief Scientific Officer and Chief Development Officer at 4SC AG. In addition, Immunic has appointed Dr. Hella Kohlhof as new Chief Scientific Officer (CSO) as of January 1, 2017.

Over the last years, she has served as Manager Translational Pharmacology and later on as Director Development Products at 4SC AG. She was closely involved in non-clinical evaluation of epigenetic drugs including RORyt inhibitors, what is now the IMU-366 program at Immunic. Later on she was responsible for the clinical stage programs at 4SC AG.

Effective January 1, 2017, Dr. Thomas Taapken, was elected to the Supervisory Board of Immunic. Thomas Taapken recently joined Munich based publicly traded Medigene AG as CFO and will add significant biotech experience, financing and strategic transaction expertise to Immunic's supervisory board. Before his engagement at Medigene, Thomas was CEO and CFO at Epigenomics AG for over five years and CFO at BioTie Corp.

and its predecessor companies for six years.